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Pharyngeal carriage of Haemophilus influenzae type b (Hib) is important in the
transmission of Hib organisms, the pathogenesis of Hib disease, and the development
of immunity to the bacterium. The remarkable success of current vaccination programs
against Hib has been due in part to the effect of conjugate Hib vaccines in decreasing
carriage of Hib. This review explores evidence for this effect, and discusses the possible
mechanisms of the mucosal influence of Hib conjugate vaccines.
Many junior doctors today have not had
occasion to treat a child for Haemophilus influenzae
type b (Hib) disease. The remarkable absence of
cases of  this disease is due to the use of conjugate
vaccines. In countries with established Hib vaccina-
tion programs the incidence of disease has declined
sharply (1). In fact, in some countries protection
provided by Hib conjugate vaccines appears to ex-
tend to unvaccinated infants in the population (2,3).
This phenomenon has been attributed to the conju-
gate vaccines’ effect of decreasing Hib colonization;
however, few controlled studies have been conducted
in this area and many aspects of the Hib conjugate
vaccines’ influence on carriage remain speculative.
This review explores Hib carriage in the context of
current efforts at elucidating the effect of conjugate
vaccines on Hib within human mucosae.
What Is Carriage?
A carrier is a person who harbors a specific in-
fectious agent in the absence of clinical illness with
or without a detectable immune response (4). The
carrier state may reflect carriage of the organism in
the incubation period before clinical symptoms ap-
pear, during an illness, or after recovery from illness.
The carrier state may be short or long, and it may
be intermittent or continuous. Carriers may spread
infection to others. Latency should be distinguished
from the carrier state, in that a latent organism is
not transmissible. Hib carriage can be synonymous
with Hib colonization and is defined as the presence
of viable Hib organisms in the human pharyngeal
mucosa. This definition depends on the sensitivity
and specificity of  the process used to identify viable
bacteria in a healthy host.
The Detection of Carriage
Because Hib carrier status is usually determined
by culture techniques, the efficiency of every step in
the microbiologic investigation must be maximized.
Potential problems in the microbiologic detection of
Hib include consistency of swabbing technique,
which is difficult to maintain; survival of the  or-
ganism during transport on the swab to the culture
medium; and the morphologic similarity of Haemo-
philus species on solid media, their fastidious growth
requirements, and the abundance of other bacteria
in the specimens.
The development of an antiserum agar culture
method by Michaels et al. (5) has overcome some of
the problems in isolating Hib from a sample
containing mixed flora. This method has been suc-
cessfully modified for use in large scale studies (6).
Pharyngeal swabs are plated onto a transparent
solid medium impregnated with high-titer antise-
rum for the serotype b capsular polysaccharide.
Isolated Hib colonies in a mixed culture are readily
recognized on this medium because they are sur-
rounded by halos of antigen-antibody precipitate.
Most surveys of Hib carriage use Michaels’ anti-
serum agar method to establish carrier status.
Before this method became available, the diversity
of culture methods used to isolate Hib from pharyn-
geal swabs was a major factor complicating the
interpretation of data from different studies. In most
investigations, difficulties in isolating Hib may have
contributed to an underestimate of Hib carriage
rates.
The Epidemiology of Hib Carriage
The most important factors contributing to the
epidemiology of Hib carriage are social and demo-
graphic. The probability of Hib carriage in a young
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child seems closely related to the likelihood of expo-
sure to the organism.
Most surveys agree that nasopharyngeal or
throat cultures recover Hib in 3% to 5% of young
children (7,8), with age being a prominent determi-
nant of Hib carriage rates (9). Carriage rates are
low in the first 6 months of life, reach a maximum
between the ages of 3 and 5 years, and gradually
decline in adulthood. Under circumstances of crowd-
ing or Hib disease within a closed population, the
carriage rate may be substantially higher (7,10,11).
Hib carriage rates among children increase with the
number of siblings in a family (9), and in the United
States, especially after the occurrence of Hib dis-
ease in a child care center, carriage rates of 50% have
been found (12). The influence of concurrent upper
respiratory symptoms on Hib carriage rates remains
controversial, and studies differ in their findings on
the influence of season, sex, and race on carriage
rates. Most studies find no association of Hib car-
riage with these factors. Antimicrobial therapy
affects Hib carriage; in particular, if given appropri-
ately, rifampicin may eliminate throat carriage of
Hib and reduce the risk for secondary disease among
contacts (13).
Longitudinal studies of children further charac-
terize Hib carriage. Although many children may
be transient carriers of Hib (14), carriage tends to
persist for many weeks or months (10,12,13). It
seems that close contact and generous exchange of
respiratory secretions is required for the transmis-
sion of Hib between hosts. Even when the contact
between a known carrier and a susceptible child is
intimate, spread of Hib occurs slowly over weeks or
months (7,8). Bijlmer has suggested that village
population dynamics and living conditions in the
Gambia contribute to different kinetics of coloniza-
tion and transmission of Hib, as persistence of
carriage in Gambian children is short-lived (15).
Hib Carriage and the Transmission of Disease
Since most patients with Hib disease have not
had contact with a person who had invasive disease,
and the organism has no known reservoir outside
humans, asymptomatic carriers have been recog-
nized as the major source of infection. The
relationship between carriage rates and the risk for
disease is not simple. The spread of infection in the
presence of low carriage rates has been described
(16), and no overt disease has been reported despite
high carriage rates (7,17). Furthermore, organisms
isolated from the pharynx appear to lack certain
virulence attributes found in organisms isolated
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from patients with invasive disease (18).
Like surveys of Hib carriage, epidemiologic
surveys of Hib disease have found that rapid dis-
semination of Hib strains has not been the rule,
although the temporal clustering of several episodes
of systemic disease in child care centers has occurred.
The secondary attack rate for household contacts is
approximately 500 times higher than the endemic-
disease risk for the general population (1). The high
frequency of Hib carriage in homes and child care
centers of  patients who have Hib disease suggests
either that a high concentration of carriers precedes
and increases the probability of cases, or that af-
fected children are potent sources of infection for
others in close contact.
Although encapsulation enhances the ability to
survive the dehydrating stress that occurs during
transfer between hosts (20), a great deal remains
unknown about the transmission of Hib. What are
the modes of transmission between hosts? How long
can organisms remain viable between hosts? Is there
a threshold colonizing population or dose of organ-
isms to ensure successful transmission? Is there any
correlation between the size of the infective dose or
the number of carried organisms and the likelihood
of invasive disease?
Hib Carriage and the Pathogenesis of Disease
The accepted pathogenesis of invasive Hib dis-
ease begins with the pharynx as the portal of entry.
The infant rat model of H. influenzae meningitis has
been used to study the early pathogenic events of
Hib disease. Infant rats contracted meningitis after
intranasal challenge with Hib (21). There was an
age-dependent susceptibility to meningeal invasion
(22), and bacteremia followed the nasopharyngeal
inoculation of organisms. The incidence of bacterial
meningitis, irrespective of rat host age, was directly
related to the intensity of bacteremia (22).  To reach
the bloodstream, this nonmotile bacterium must
pass through or between epithelial cells, penetrate
the basement membrane and subepithelial tissue,
and enter the endothelium of a blood vessel. The
manner by which this occurs remains under inves-
tigation.
Untreated, Hib meningitis and epiglottitis are fa-
tal in most cases. The death of the host is
disadvantageous to the infecting bacterium since
death terminates transmission and propagation of
organisms. Vascular invasion by Hib may be circum-
stantial or accidental rather than the result of
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Hib Carriage and the Development of Immunity
The capsular polysaccharide of Hib is a linear
polymer of ribose, ribitol, and phosphate (23) and is
called polyribosylribitol phosphate (PRP). PRP is the
principal determinant of virulence of Hib (24,25) and
a target for antibody-mediated immunity. Consid-
erable evidence indicates that antibody to PRP is a
principal protective host factor (26).
At birth, maternal anti-PRP IgG confers protec-
tion; however, as the level of maternal antibody in
the infant declines, the risk for and incidence of Hib
disease rise. As children approach 2 years of age,
their own antibody to the capsular polysaccharide
begins to appear. The antigenic stimulus for this age-
dependent development of bactericidal activity may
be through mucosal exposure to Hib or to other cross-
reacting antigens (27).
High serum anti-capsular antibody concentra-
tions are associated with the Hib carrier state in
children older than 18 months (17,28), but how colo-
nization increases serum anti-PRP antibody
concentrations remains unclear. Hib antigen may be
absorbed across the mucosa, or the whole organism
may traverse this barrier during colonization, caus-
ing low grade asymptomatic bacteremia and a
systemic antibody response. It is possible that Hib
organisms are phagocytosed by lymphoid cells, in
the pharyngeal mucosa, that may act as antigen-
presenting cells (29), leading to the production of
specific serum or mucosal antibodies, with or with-
out direct vascular invasion by the organism. Other
mucosal surfaces, such as the gastrointestinal mu-
cosa, may play a role in anti-PRP immunogenesis.
The incidence of bacteremia and meningitis in in-
fant rats was significantly lower for rats fed with
Escherichia coli that possessed K100 capsular anti-
gen (cross-reactive with type b capsular antigen)
than for rats fed with E. coli K92 or saline (30).
Many have argued that the high prevalence of
anti-PRP antibodies and the low rates of Hib car-
riage in children point to sources other than Hib that
give rise to serum anti-PRP antibodies. However, the
technical difficulties in identifying Hib carriage may
have led to an underestimate of carriage rates. With
more sensitive culture techniques, it now seems
more plausible that Hib carriage or infection could
account for the acquisition of natural immunity.
Vaccination and Hib Disease
The initial development of vaccines against Hib
in the late 1960s was prompted by three major con-
cerns: the high case-fatality rate of Hib disease, the
high incidence of central nervous system sequelae
in children surviving Hib meningitis, and the
gradual emergence of strains resistant to preferred
antibiotics. Because serum anti-PRP antibodies were
known to be a principal protective factor in the host,
efforts were made to increase the antibody concen-
tration by active immunization with a vaccine
composed of purified capsular polysaccharide. While
the PRP vaccine was effective in protecting healthy
children 18 months of age and older against inva-
sive Hib disease (with an estimated efficacy of 90%),
it did not protect younger children who have the
highest incidence of Hib disease (31).
The explanation for the vaccine’s inability to pro-
tect younger children lies in the chemistry of the
capsular material. PRP, a heteropolymer of pentose
sugars, does not elicit a T-cell–dependent immune
response and is not an efficient immunogen, espe-
cially in young children. Carbohydrate antigens,
such as these capsular polysaccharides of
encapsulated bacteria, are characterized as T-cell-
independent type 2 (TI-2) antigens. However, for
many antigens the classification T-cell–independent
or T-cell–dependent refers more to the pattern of an-
tibody response than to the involvement of  T-cells
in eliciting that response. In the very young, the an-
tibody response to T-cell–independent antigens is
low, consists of a high proportion of IgM antibody,
and there is no booster response to repeated doses
of antigen.
Converting polysaccharide into a T-cell–de-
pendent antigen, to which infants can respond, re-
quires the covalent linkage to protein molecules, thus
producing a conjugate vaccine. Studies of the differ-
ent conjugate vaccines have confirmed that
conjugation results in a T-cell–dependent response
(32). Even though the protein carriers and covalent
linkages are biochemically and structurally differ-
ent, they appear to be more immunogenic than pure
PRP vaccines. Conjugate vaccines can confer pro-
tection against Hib in infants under 6 months of age
(33).
Four conjugate vaccines have undergone clinical
evaluation: PRP-D (Connaught Laboratories), PRP-
T (Pasteur-Merieux), PRP-OMPC (Merck Sharp and
Dohme), and HbOC (Praxis Biologicals). Each of
these vaccines is distinguished by its carrier mol-
ecule, the size of the hapten saccharide, the type of
linkage between hapten and carrier, and the ratio
of polysaccharide to protein. These physicochemical
differences between the vaccines influence their im-
munogenicity. Additionally, dose variation, such as
the age at which the primary series of two or three
immunizations is given and the interval between
each dose of vaccine, may affect the level of anti-
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body response and/or the protection provided.
The concentration of vaccine-induced serum an-
tibody against Hib needed for protection is not
precisely known. The issue is complicated as simi-
lar concentrations of antibodies may vary in
functional activity (34). The maintenance of a thresh-
old concentration of serum anti-PRP antibody may
not be necessary if immunized children are primed
for an effective booster response on exposure to Hib.
Efficacy studies have shown that PRP-D, HbOC,
PRP-OMP, and PRP-T can prevent more than 90%
of Hib disease (1,33,35,37). However, PRP-D proved
to be ineffective in preventing Hib disease in an ef-
ficacy trial among Alaskan children (38). Thus, the
choice between the conjugate vaccines may be criti-
cal only in populations in which infection pressure
is very high, and the age of greatest incidence of
disease is low. In these populations, conjugate vac-
cines with high immunogenicity at the first dose may
be the best to use (39), so that the youngest children
at the highest risk are afforded some protection at
the earliest opportunity. In most populations, the
choice of vaccine has to be based on other factors,
the most important of which is cost.
Conjugate Vaccination and Hib Carriage
After a 4-year national immunization program
for infants in Finland, Takala et al. (40) reported
that Hib colonization was less prevalent among 327
children vaccinated with PRP-D vaccine than among
398, previously studied, unvaccinated children (0%
vs 3.5%). The children studied were healthy 3-year-
olds, from whom throat swabs were taken during a
well-child visit to their local health center. However,
the control cultures were obtained before the na-
tionwide vaccination study; thus temporal factors
other than vaccination may have influenced the re-
sults. Geographic factors necessitated sending swabs
by mail to the center of sample processing, which
may have limited the sensitivity of the microbiologic
assay. Additionally, possible exposure to the bacte-
rium from contacts was not measured.
In child care centers in Dallas, a prospective study
was done to determine the prevalence of Hib coloni-
zation between 1987 and 1989 (41). During this
period, conjugate vaccination was introduced in the
United States, so both vaccinated and unvaccinated
children attended  the centers. Of  283 children stud-
ied, 59 had received unconjugated polysaccharide
vaccine, and 89 had  received conjugate vaccine (of
which 94% received PRP-D). The Hib acquisition
rates over the surveillance period were 21% and 9%,
respectively.  Among children exposed to at least one
child with a positive culture result, the efficacy of
conjugate vaccination to prevent Hib colonization
in an unmatched analysis was 64%. No effect on colo-
nization was found with PRP vaccination.
A clinic-based study in metropolitan Atlanta
found a decreased Hib carriage rate in a population
of 2- to 5-year-old children, 75% of whom were vac-
cinated with an Hib conjugate vaccine (42), and in
Apache and Navajo Indian children who had re-
ceived the Hib-OMPC vaccine appropriate for their
age (43). These studies were performed after vacci-
nation programs had begun, when adequate control
populations were not available, and logistic factors
often necessitated suboptimal microbiologic proce-
dures.
The district by district implementation of a con-
jugate vaccine (PRP-T) in the Oxford Region in
England enabled examination of a conjugate
vaccine’s effects over time in contemporary groups
of vaccinated and unvaccinated infants (44). The
children were recruited at birth so as to minimize
selection bias concerning Hib carriage. Sampling
error was limited, as one person took all the throat
swabs, and laboratory analysis was standardized and
took place in a single center. Other factors that could
have influenced exposure to Hib or susceptibility to
carriage were subjected to statistical control. Infants
who had received Hib conjugate vaccine at the ages
of 2, 3, and 4 months had significantly lower Hib
acquisition rates than controls. In accordance with
this, the point prevalence of Hib carriage was con-
sistently lower in vaccines than in controls at 6, 9,
and 12 months of age. The rates of acquisition and
the period prevalence of  H. influenzae serotypes e
and f did not differ between vaccines and controls.
How Does Conjugate Vaccine Against
Hib Affect Carriage?
The unconjugated Hib polysaccharide vaccine
raises the IgA antibody concentration in nasal se-
cretions and saliva of both adults and children (45).
However, it does not affect the oropharyngeal car-
riage of Hib (31). The same lack of effect on
pharyngeal carriage has been seen with other
parenterally administered polysaccharide vaccines:
meningococcal group  A and C and several serotypes
in the Streptococcus pneumoniae polysaccharide
vaccine (47,48).
Conjugate vaccines induce higher concentrations
of serum anti-PRP antibodies in young children than
polysaccharide vaccines. It has been suggested that
high serum concentrations might lead to passive
transudation of IgG antibodies to mucosal surfaces
(49). In an infant rat model, the serum IgG anti-
body concentration needed for an effect on Hib
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colonization was 7 µg/mL (50). More recent research
has found that the presence and concentration of
IgG anti-PRP antibodies in saliva correlated with
the concentration in serum after conjugate vaccina-
tion (51). Secretory IgA anti-PRP antibody was found
in the saliva of children who had no similar, detect-
able serum IgA. This suggests that the anti-PRP IgG
in saliva was derived from serum, whereas the IgA
antibodies were locally produced.  It seems that con-
jugate vaccines can induce a mucosal IgA response
as well as a systemic IgG response, and while there
is some evidence that high serum levels of IgG are
relevant to the prevention of acquisition of carriage,
the role of IgA remains unclear.
A decline in the serum, and thus perhaps mu-
cosal, anti-PRP antibody concentration after primary
immunization offers a simple explanation for the
time-dependent effect of conjugate vaccines on ac-
quisition of Hib. The geometric mean titer (GMT) of
serum anti-PRP antibody in children in Oxfordshire,
at 5 months of age, soon after completing a course
of Hib immunization, was 5 µg/mL (52). The GMT
in these children at 12 months of age was 0.83 µg/
mL (53). A concentration of 1µg/mL after immuni-
zation with Hib polysaccharide vaccine has been
accepted as the concentration associated with long
term protection against invasive Hib disease (54).
Acquisition of Hib and prolonged Hib carriage may
occur only below a threshold concentration of serum
or mucosal antibody.
How specific antibody contributes to the demise,
or inhibits the attachment of Hib in the pharyngeal
mucosa remains unresolved. Possible mechanisms
include antibody-mediated opsonophagocytosis, di-
rect bactericidal activity, or stereotactic inhibition.
However, simple antibody-mediated bactericidal
mechanisms may not completely explain the modu-
lation of colonization in vaccinated persons. Carriage
was not rapidly curtailed when conjugate vaccine
was administered to current Hib carriers (44). This
result is not easily explained, although the intra-
cellular sequestration of Hib (55) may render a
source of organisms inaccessible to antibodies in se-
cretions. It is also possible that conjugate vaccine
does not add significant antigenic stimulus in a child
carrying Hib, with Hib antigen present in the mu-
cosa.
Vaccines against Hib intervene in the normal re-
lationship between Hib and host by increasing
serum and/or mucosal anti-PRP antibody concen-
trations in the host before the host has any exposure
to the bacterium. One could speculate that the pri-
mary role of vaccines in limiting Hib colonization is
to prevent the acquisition of organisms. Secondarily,
a large boost in the antibody concentrations, caused
by mucosal contact with Hib in an immunized host,
could lead to the more rapid elimination of Hib from
the mucosa. There is also tenuous evidence of de-
creased Hib colony counts in cultures from colonized,
vaccinated children (28).
In ecologic terms, Hib may precariously occupy
the pharynx. A small influence that upsets the ecol-
ogy in vaccinated persons may have a profound effect
on the population kinetics of Hib. A rise in the
concentration of serum and mucosal anti-PRP anti-
bodies in infants could be enough to dramatically
affect the pattern of Hib transmission. It seems likely
that this effect would initially be greatest in places
of close contact between children: families and child
care institutions. Subsequently, the effect would be-
come evident in a more widespread population.
The paucity of data on the ecologic behavior of
Hib in the pharynx, the influence of conjugate vac-
cines on this behavior, and the importance of this
influence, have prompted attempts at mathemati-
cal modeling to predict the population kinetics of
Hib carriage and disease after conjugate vaccina-
tion. These models remain in their infancy but are
awaited with interest.
Because they differ in biochemical composition
and immunogenicity, the conjugate vaccines may
vary in their long-term protective efficacy and ef-
fect on Hib carriage and transmission. Additionally,
differing immunization regimens in populations may
affect any generation of herd immunity. For example,
administering a booster dose of conjugate Hib vac-
cine after the age of 12 months may prolong the
presence of high concentrations of anti-PRP anti-
body in children, thereby enhancing the potential
to limit transmission of Hib in the population.
In their relationship with the human host,
Neisseria meninigitidis,  S. pneumoniae, and Hib
have numerous and close parallels. With the use of
principles similar to those applied to Hib vaccines,
conjugate vaccines against these other encapsulated
pathogenic bacteria are now being developed and
tested. The findings in studies of Hib may be a para-
digm for the effect of conjugate vaccines on
colonization by N. meninigitidis and S. pneumoniae.
It will be important to examine this possibility
closely as the vaccines become available.
The effect of conjugate vaccines on Hib carriage
has been established in epidemiologic terms, but mo-
lecular knowledge about vaccination and mucosal
immunity is limited. Much remains to be learned
about the interaction between host and bacterium
at the mucosal surface and about the contribution
of conjugate vaccines to this complex relationship.Vol. 2, No. 3—July-September 1996 Emerging Infectious Diseases 181
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